Curis (STU:CUS1) Net Interest Margin (Bank Only) %


STU:CUS1 Curis Inc STU:CUS1
50 GF Score
Price €5.96
GF Value €1.47
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:CUS1
50GF Score
Curis Inc STU:CUS1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Curis (STU:CUS1) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €5.96 is trading 305.4% above its estimated GF Value™ of €1.47. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for STU:CUS1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1.47 vs. price of €5.96 (305.4% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the STU:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CRIS:USACUS0:Germany
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
50GF Score

Get the complete analysis for STU:CUS1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.96
Price
€1.47
GF Value